SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-Ocumension Therapeutics Says Approval Received For A Phase III Clinical Trial Of Ot-703 In China

reuters.com · 06/09/2022 06:34
BRIEF-Ocumension Therapeutics Says Approval Received For A Phase III Clinical Trial Of Ot-703 In China

- Ocumension Therapeutics OCUTF:

  • APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-703 IN CHINA FROM CDE OF NMPA


Further company coverage: OCUTF


((Reuters.Briefs@thomsonreuters.com;))